Current stock page

Stock Analysis

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

PROCEPT BioRobotics Corporation (PRCT) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PRCT Stock Analysis Summary

PROCEPT BioRobotics Corporation (PRCT) currently has an AIQ Score of 49/100, indicating a bearish setup. Momentum is the strongest factor at 60/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

PRCT at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$25.18
AIQ Score49/100
Overall ViewBearish
Technical Analysis ConsensusStrong Buy
Market Cap$1.36B
P/E Ratio (TTM)-11.77
Forward P/E—
EPS (Q3 FY2026)-$0.46
Revenue (Q3 FY2026)$98.29M
Dividend Yield (TTM)0.00%
Beta1.01
Volume2.05M
52-week range$16.67-$38.11
RSI 1469.03
50-Day SMA$19.52
200-Day SMA$22.91
Analyst Price Target$30.00
Next EarningsFeb 24, 2027
As of Nov 18, 2026 · Market close

PRCTPROCEPT BioRobotics Corporation

Healthcare / Medical - Devices

Low Priority

In Line With Peers

BearishEdge 5/10
$25.18+$1.40 (+5.89%)

Latest quote

  • Momentum
    60
  • Value
    38
  • Quality
    45
  • Risk resilience
    45
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

PRCT Stock Analysis Summary

PROCEPT BioRobotics Corporation (PRCT) currently has an AIQ Score of 49/100, indicating a bearish setup. Momentum is the strongest factor at 60/100. Value is the weakest current factor at 38/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, PRCT has AIQ Score of 49/100 with Momentum base of 60/100 and fading Value at 38/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (60/100) leads while Value (38/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 5.89% stock move · PRCT classified in Medical - Devices.

Current Evidence

BearishPRCT is in a bearish AIQ regime; Momentum is the strongest visible factor at 60/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PRCT Bullish or Bearish Right Now?

PRCT currently has a bearish overall setup. Momentum is the strongest factor at 60/100, while Value is weakest at 38/100. The current evidence suggests a bearish setup.

Bull Case
  • - Price is +21.95% above its 50-day SMA.
  • - Analyst target implies +19.14% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 7).
Bear Case
  • - Value is the current constraint at 38/100.
  • - Risk Resilience is weak at 45/100.

Current Consensus

PRCT's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. PRCT's 14-day RSI is 69.03, which places the stock in a constructive momentum range. PRCT's beta is 1.01, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in PRCT?

The largest recent change in PRCT is Momentum moving up by 8.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+3.0
Momentum
+8.0
Quality
+0.0
Risk
+1.0

What Would Change the PRCT Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PRCT Decision Framework

Public evidence layers, setup checks, and risk context for PROCEPT BioRobotics Corporation.

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

PROCEPT BioRobotics Corporation has an AIQ Score of 49/100 in a Bearish regime. Momentum is strongest at 60/100. Beta is 1.01, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPRCT is in a Bearish AIQ regime with score 49/100.
Signal ConflictThe primary conflict is that momentum leads at 60/100 while value lags at 38/100.
Factor EvidenceMomentum 60/100 · Value 38/100 · Quality 45/100 · Risk 45/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 60/100.

TimingWait

Momentum is 60/100 and RSI (14) is 69.0.

Regime fitFail

PRCT is in a Bearish regime at 49/100.

Risk controlFail

Risk factor is 45/100 with beta 1.01 and annual volatility 65.89%.

ConflictWait

Current conflict: momentum leads at 60/100 while value lags at 38/100.

AIQ Score
49/100
Price
$25.18
Beta
1.01
RSI (14)
69

PRCT Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PRCT Fundamentals

PRCT valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$98.29M
Net income
-$26.52M
Free cash flow
-$9.65M
View full PRCT fundamental analysis

PRCT Technical Analysis

PRCT technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
69.03
Price vs SMA-50
+21.95%
View full PRCT technical analysis

PRCT Stock Catalysts

Track PRCT earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$30.00
News items
4
View PRCT earnings and stock catalysts

PRCT Dividend Analysis

PRCT dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PRCT dividend history and analysis

PRCT Financial Data

PRCT revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$98.29M
EPS
-$0.46
Periods
8
View PRCT financials

PRCT Risk Analysis

PRCT volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.01
Risk score
45/100
1Y volatility
65.89%
View PRCT risk analysis

PRCT Stock News

PRCT stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 18, 2026
Sentiment
—
Read PRCT stock news

PRCT vs Medical - Devices Peers

Current peer cohort: PRCT · SNN · TNDM · UFPT · ATEC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PRCT
Current stock
49/10038/10060/10045/100-0.1165.89%Current
SNN
Smith & Nephew plc
70/10079/10060/10075/100-0.227.30%PRCT vs SNN
TNDM
Tandem Diabetes Care, Inc.
55/10064/10059/10038/1000.4975.74%PRCT vs TNDM
UFPT
UFP Technologies, Inc.
68/10061/10081/10056/1000.6950.83%PRCT vs UFPT
ATEC
Alphatec Holdings, Inc.
48/10061/10047/10028/100-0.9478.93%PRCT vs ATEC
Pairwise Compare links: SNN · TNDM · UFPT · ATECPRCT vs SNNPRCT vs TNDMPRCT vs UFPTPRCT vs ATECCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PRCT stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PRCT: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-11.77
As of Nov 18, 2026
Revenue growth
17.96%
Gross margin
64.66%
Current debt / equity
0.23
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$98.29M
Quarter net income
-$26.52M
Quarter free cash flow
-$9.65M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bullish
RSI 14
69.03
MACD
1.16

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
45/100
Beta
1.01
Annual volatility
65.89%
Max drawdown
-53.77%

PRCT Stock FAQ

What is PRCT stock price today?

PROCEPT BioRobotics Corporation's current stock price is $25.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PRCT bullish or bearish right now?

PRCT's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PRCT's market cap?

PRCT's market cap is $1.36B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PRCT's current P/E ratio?

PRCT's current P/E ratio is -11.77 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PRCT's RSI?

PRCT's 14-day RSI is 69.03 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PRCT above its 50-day and 200-day moving averages?

PRCT is 21.95% from its 50-day SMA and 3.90% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PRCT's next earnings date?

PRCT's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PRCT pay a dividend?

PRCT's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.